Linguamatics Ltd, a provider in enterprise text mining for the life science and other markets, recently announced that Novo Nordisk, a world–leader in diabetes care, has entered into a multi–year agreement to use the I2E semantic knowledge discovery platform for text mining. At Novo Nordisk I2E will be used to mine published literature and internal information sources to provide business critical intelligence for R&D decision makers. Financial details of the agreement were not disclosed.

I2E’s natural language processing (NLP) based text mining delivers relevant, high quality and current insights from content such as biomedical literature, internal reports, patents and news sources to inform business decisions. It is used for a wide variety of life science applications including biomarker discovery, target selection, safety/tox, pharmacogenomics, systems biology, competitor intelligence and sentiment analysis.

"Deriving high value, up–to–date intelligence from unstructured textual data enables Novo Nordisk to make better–informed project decisions,"  said Henning Nielsen, Director, Library and Information Centre at Novo Nordisk. "We recognize the value that the right text mining tool can provide, and have chosen I2E for its flexibility and range of capabilities including NLP."

To read full press release, click here.

This BeyeNETWORK news item contains information from a recent press release by the company mentioned.